dan 2163 has been researched along with Hyperprolactinaemia in 30 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Risperidone and amisulpride caused hyperprolactinemia and macroprolactinemia; thus, detection of MPRL in the clinical setting should be performed as this phenomenon appears early in treatment (the second week) and continues, that can avoid unnecessary examination and treatment for asymptomatic patients with macroprolactinemia." | 8.12 | Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride. ( Haiying, J; Haizhi, C; Jianhua, L; Jianjun, L; Jing, L; Lilei, L; Xiaocong, F; Zhenhua, W, 2022) |
| " We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)." | 7.79 | Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013) |
| "Relapse was determined by assessing changes in Positive and Negative Syndrome Scale (PANSS) total scores from baseline to 6 months (increased over 20% or 10% reaching 70)." | 5.91 | Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics. ( Cai, J; Gao, M; Huang, J; Huang, Y; Kang, D; Li, L; Liu, F; Long, Y; Ou, J; Peng, X; Shao, P; Shao, T; Shen, Y; Song, C; Su, Y; Sun, M; Wang, W; Wang, X; Wu, Q; Wu, R; Xiao, J; Xie, P; Yang, Y, 2023) |
| " Furthermore, this case suggests that changing the regimen to aripiprazole with propranolol may be a potential option for amisulpride withdrawal akathisia superimposed on pre-existing hyperprolactinemia." | 4.12 | Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report. ( Kim, SG; Seo, EH; Yang, HJ; Yoon, HJ, 2022) |
| "Risperidone and amisulpride caused hyperprolactinemia and macroprolactinemia; thus, detection of MPRL in the clinical setting should be performed as this phenomenon appears early in treatment (the second week) and continues, that can avoid unnecessary examination and treatment for asymptomatic patients with macroprolactinemia." | 4.12 | Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride. ( Haiying, J; Haizhi, C; Jianhua, L; Jianjun, L; Jing, L; Lilei, L; Xiaocong, F; Zhenhua, W, 2022) |
| " We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)." | 3.79 | Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013) |
| "The mean dosage of amisulpride was 195." | 2.77 | Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients. ( Kang, SG; Kim, TW; Lee, BH; Lee, HJ; Park, YM; Yoon, HK, 2012) |
| "We have investigated the categorical prevalence of hyperprolactinemia and examined the relationship between prolactin levels and subjective endocrine-related adverse effects in schizophrenia patients treated with amisulpride during a 1-year period." | 2.77 | Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride. ( Ahn, YM; Jung, DC; Kim, EY; Kim, SH; Kim, YS; Lee, NY, 2012) |
| "The trial was a prospective, open-label, single-center one with a flexible dosing of SGAs." | 2.73 | Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. ( Cejpková, A; Rodáková, I; Svestka, J; Synek, O; Tomanová, J, 2007) |
| "Relapse was determined by assessing changes in Positive and Negative Syndrome Scale (PANSS) total scores from baseline to 6 months (increased over 20% or 10% reaching 70)." | 1.91 | Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics. ( Cai, J; Gao, M; Huang, J; Huang, Y; Kang, D; Li, L; Liu, F; Long, Y; Ou, J; Peng, X; Shao, P; Shao, T; Shen, Y; Song, C; Su, Y; Sun, M; Wang, W; Wang, X; Wu, Q; Wu, R; Xiao, J; Xie, P; Yang, Y, 2023) |
| "Antipsychotic drugs are the mainstay of treatment in schizophrenia." | 1.35 | Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases. ( Akkaya, C; Ersoy, C; Kaya, B; Kirli, S; Kotan, Z; Sarandol, A, 2009) |
| " No significant correlation was detected between prolactin levels and either amisulpride dosage or duration of administration." | 1.34 | Amisulpride-induced hyperprolactinemia is reversible following discontinuation. ( Liappas, J; Mourikis, I; Paparrigopoulos, T; Soldatos, C; Tzavellas, E, 2007) |
| "Risperidone monotherapy treatment was associated with hyperprolactinaemia in 69% of patients ( n = 35) and in 100% of female patients (n = 16) and amisulpride monotherapy in 100% (n = 7)." | 1.34 | Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. ( Bushe, C; Shaw, M, 2007) |
| " However, no correlation between prolactin levels and dosage could be found." | 1.32 | [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics]. ( Fric, M; Laux, G, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (56.67) | 29.6817 |
| 2010's | 9 (30.00) | 24.3611 |
| 2020's | 4 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lange, JH | 1 |
| Reinders, JH | 1 |
| Tolboom, JT | 1 |
| Glennon, JC | 1 |
| Coolen, HK | 1 |
| Kruse, CG | 1 |
| Yang, HJ | 1 |
| Kim, SG | 1 |
| Seo, EH | 1 |
| Yoon, HJ | 1 |
| Prasannakumar, A | 1 |
| Suhas, S | 1 |
| Kumar, V | 1 |
| Cai, J | 1 |
| Li, L | 1 |
| Shao, T | 1 |
| Sun, M | 1 |
| Wang, W | 1 |
| Xie, P | 1 |
| Wang, X | 1 |
| Yang, Y | 1 |
| Long, Y | 1 |
| Kang, D | 1 |
| Xiao, J | 1 |
| Su, Y | 1 |
| Peng, X | 1 |
| Huang, Y | 1 |
| Gao, M | 1 |
| Wu, Q | 1 |
| Song, C | 1 |
| Liu, F | 1 |
| Shao, P | 1 |
| Ou, J | 1 |
| Shen, Y | 1 |
| Huang, J | 1 |
| Wu, R | 1 |
| Zhenhua, W | 1 |
| Haizhi, C | 1 |
| Jing, L | 1 |
| Xiaocong, F | 1 |
| Jianhua, L | 1 |
| Jianjun, L | 1 |
| Lilei, L | 1 |
| Haiying, J | 1 |
| Düring, SW | 1 |
| Nielsen, MØ | 1 |
| Bak, N | 1 |
| Glenthøj, BY | 1 |
| Ebdrup, BH | 1 |
| Voicu, V | 1 |
| Medvedovici, A | 1 |
| Ranetti, AE | 1 |
| Rădulescu, FŞ | 1 |
| Kalkavoura, CS | 1 |
| Michopoulos, I | 1 |
| Arvanitakis, P | 1 |
| Theodoropoulou, P | 1 |
| Dimopoulou, K | 1 |
| Tzebelikos, E | 1 |
| Lykouras, L | 1 |
| Pasquini, M | 1 |
| Berardelli, I | 1 |
| Calabrò, F | 1 |
| Roselli, V | 1 |
| Hefner, S | 1 |
| Biondi, M | 1 |
| Akkaya, C | 1 |
| Kaya, B | 1 |
| Kotan, Z | 1 |
| Sarandol, A | 1 |
| Ersoy, C | 1 |
| Kirli, S | 1 |
| Chen, YY | 1 |
| Huang, MC | 1 |
| Wu, KC | 1 |
| Saitis, M | 1 |
| Papazisis, G | 1 |
| Katsigiannopoulos, K | 1 |
| Kouvelas, D | 1 |
| Tschoner, A | 1 |
| Engl, J | 1 |
| Rettenbacher, MA | 1 |
| Kaser, S | 1 |
| Ott, HW | 1 |
| Fleischhacker, WW | 1 |
| Patsch, JR | 1 |
| Ebenbichler, CF | 1 |
| Höfer, P | 1 |
| Friedrich, F | 1 |
| Vyssoki, B | 1 |
| Spindelegger, C | 1 |
| Schmook, M | 1 |
| Barnas, C | 1 |
| Lesch, OM | 1 |
| Walter, H | 1 |
| Ružić, K | 1 |
| Grahovac, T | 1 |
| Graovac, M | 1 |
| Dadić-Hero, E | 1 |
| Sepić-Grahovac, D | 1 |
| Sabljić, V | 1 |
| Lee, BH | 1 |
| Kang, SG | 1 |
| Kim, TW | 1 |
| Lee, HJ | 1 |
| Yoon, HK | 1 |
| Park, YM | 1 |
| Kim, EY | 1 |
| Kim, SH | 1 |
| Lee, NY | 1 |
| Jung, DC | 1 |
| Kim, YS | 1 |
| Ahn, YM | 1 |
| Lee, SJ | 1 |
| Lee, JH | 1 |
| Jung, SW | 1 |
| Koo, BH | 1 |
| Choi, TY | 1 |
| Lee, KH | 1 |
| Marchese, G | 2 |
| Ruiu, S | 2 |
| Casti, P | 2 |
| Saba, P | 2 |
| Gessa, GL | 2 |
| Pani, L | 2 |
| Fric, M | 1 |
| Laux, G | 1 |
| Bressan, RA | 1 |
| Erlandsson, K | 1 |
| Spencer, EP | 1 |
| Ell, PJ | 1 |
| Pilowsky, LS | 1 |
| Bliesener, N | 1 |
| Yokusoglu, H | 1 |
| Quednow, BB | 1 |
| Klingmüller, D | 1 |
| Kühn, KU | 1 |
| Kopecek, M | 2 |
| Bares, M | 2 |
| Svarc, J | 1 |
| Dockery, C | 1 |
| Horácek, J | 2 |
| Paparrigopoulos, T | 1 |
| Liappas, J | 1 |
| Tzavellas, E | 1 |
| Mourikis, I | 1 |
| Soldatos, C | 1 |
| Paulzen, M | 1 |
| Gründer, G | 1 |
| Peritogiannis, V | 1 |
| Goulia, P | 1 |
| Pappas, D | 1 |
| Hyphantis, T | 1 |
| Mavreas, V | 1 |
| Bushe, C | 1 |
| Shaw, M | 1 |
| Svestka, J | 1 |
| Synek, O | 1 |
| Tomanová, J | 1 |
| Rodáková, I | 1 |
| Cejpková, A | 1 |
| Bartholini, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Therapy With Bromocriptine in Patients With Symptomatic Risperidone-Induced Hyperprolactinemia[NCT00315081] | Phase 3 | 20 participants | Interventional | 2006-05-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for dan 2163 and Hyperprolactinaemia
| Article | Year |
|---|---|
Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Blood-Brain Barrier; Humans; Hyperprolactinemia; Is | 2013 |
Is amisulpride safe when prescribed to breast and prostate cancer patients?
Topics: Amisulpride; Antidepressive Agents; Breast Neoplasms; Depression; Female; Humans; Hyperprolactinemia | 2013 |
6 trials available for dan 2163 and Hyperprolactinaemia
| Article | Year |
|---|---|
Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients.
Topics: Adult; Amisulpride; Asian People; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Hu | 2012 |
Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Drug Tolerance; Female; Humans; Hyperprolactinemia; Male; | 2012 |
A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia.
Topics: Adult; Aged; Amisulpride; Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Disea | 2012 |
Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report.
Topics: Adult; Amisulpride; Antipsychotic Agents; Bromocriptine; Estradiol; Female; Follicle Stimulating Hor | 2004 |
Hyperprolactinemia after low dose of amisulpride.
Topics: Adult; Amisulpride; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Depression; Dr | 2004 |
Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibe | 2007 |
22 other studies available for dan 2163 and Hyperprolactinaemia
| Article | Year |
|---|---|
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolac | 2007 |
Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benztropine; Female; Humans; Hyperprolactine | 2022 |
Amisulpride-Induced High Elevation in Prolactin Levels.
Topics: Amisulpride; Antipsychotic Agents; Humans; Hyperprolactinemia; Prolactin | 2023 |
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Humans; Hyperprol | 2023 |
Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride.
Topics: Amisulpride; Antipsychotic Agents; Humans; Hyperprolactinemia; Prolactin; Risperidone; Schizophrenia | 2022 |
Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D
Topics: Adult; Amisulpride; Antipsychotic Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Fe | 2019 |
Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cabergoline; Diagnostic and Statistical Manual of Mental D | 2013 |
Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases.
Topics: Adult; Amisulpride; Antipsychotic Agents; Brain; Female; Humans; Hyperprolactinemia; Magnetic Resona | 2009 |
Weight gain in a patient with schizophrenia switched from quetiapine to amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Appetite; Dibenzothiazepines; Dose-Response Relationship, | 2008 |
Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Long-Term Care; | 2008 |
Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Diagnosis, Differential; Female; Humans; Hyper | 2009 |
Hyperprolactinaemia and acute psychosis: prolactinoma or medication-induced phenomenon?
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Female; Follow-Up Studies; Humans; Hyperprolacti | 2010 |
Hyperprolactinaemia with amisulpride.
Topics: Amisulpride; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Bo | 2011 |
Effect of the amisulpride isomers on rat prolactinemia.
Topics: Amisulpride; Animals; Dose-Response Relationship, Drug; Hyperprolactinemia; Male; Pituitary Gland; P | 2002 |
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzothiaze | 2003 |
Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Brain; Contrast Media; Dopamine D2 Receptor Antagonists; D | 2004 |
Normalization of hyperprolactinaemia after withdrawal of a low dose of amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Depressive Disorder; Female; Humans; Hyperprolactinemia; M | 2005 |
Amisulpride-induced hyperprolactinemia is reversible following discontinuation.
Topics: Adult; Aged; Amisulpride; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Hy | 2007 |
Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Drug Thera | 2007 |
Amenorrhea after sertraline introduction in an amisulpride-treated patient with undiagnosed polycystic ovary disease.
Topics: Adult; Amenorrhea; Amisulpride; Antipsychotic Agents; Depression; Drug Interactions; Female; Humans; | 2007 |
Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Bipolar Disorder; Cohort Studies; Cross-Sectional Studies; | 2007 |
Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect.
Topics: Amisulpride; Animals; Antipsychotic Agents; Binding, Competitive; Bromocriptine; Dopamine Agonists; | 2002 |